Discover
INVA
Innoviva, Inc.
21.90
2 x 16.20
2 x 28.45
bid
ask
-
0.81
3.57%
2 @ 05:51 AM
21.95 +0.05 (0.23%)
| Ytd | 9.55% | |
| 1y | 10.66% |
21.89
day range
22.89
16.52
52 week range
25.15
| Open | 22.71 | Prev Close | 22.71 | Low | 21.89 | High | 22.89 | Mkt Cap | 1.62B |
| Vol | 775.94K | Avg Vol | 775.92K | EPS | 6.26 | P/E | 3.50 | Forward P/E | 9.91 |
| Beta | 0.35 | Short Ratio | 7.15 | Inst. Own | 108.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | 09-08 | Earning | 08-05 | 50-d Avg | 22.66 | 200-d Avg | 21.17 | 1yr Est | 35.50 |
INVA News
benzinga.com
Nortiva Bio Launches Clinical-Stage Biopharmaceutical Company To Develop Long-Acting Oral Medicines
Company is advancing its proprietary LYNX™ drug delivery platform to develop oral therapies that las
benzinga.com
Innoviva Specialty Therapeutics Inks Agreement With Dr. Reddy's Laboratories To Develop, Commerciali
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced that
benzinga.com
HC Wainwright & Co. Reiterates Buy on Innoviva, Maintains $46 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Innoviva (NASDAQ:INVA) with a Buy a